Locally Advanced and BCR
nmCRPC
At 2 years, bone mets develop in 1/3 of nmCRPC and the average metastasis-free survival is 30mo in nm-CRPC. (1)
At 2 years, bone mets develop in 1/3 of nmCRPC and the average metastasis-free survival is 30mo in nm-CRPC. (1)
- Smith, M. R., et al. “Natural History of Rising Serum PSA in Men with Castrate Nonmetastatic Prostate Cancer.” Journal of Clinical Oncology, vol. 23, 2005, pp. 4514–4514.